摘要
胸腺癌是一种原发于胸腺上皮的罕见且恶性程度较高的肿瘤,完全手术切除是其首选治疗方式,而对于晚期胸腺癌患者,其治疗以综合治疗为主。研究表明,胸腺癌患者血管内皮生长因子受体2(VEGFR-2)存在过表达。作为一种小分子VEGFR-2酪氨酸激酶抑制剂,阿帕替尼可抑制肿瘤血管生成。本例个案报道中选择阿帕替尼治疗胸腺癌,阿帕替尼口服治疗3个月后病灶缩小,胸痛、胸闷、心悸、喘促症状明显减轻,胸水减少,病情得到有效控制,疗效评价为部分缓解(PR)。患者无疾病进展生存期(PFS)为11.93个月,总生存期(OS)为47.47个月。患者生活质量得到提高,生存期得到延长。
Thymic carcinoma is a rare and highly malignant tumor originating from the thymic epithelium. Although complete resection operation is the preferred treatment, comprehensive treatment is the main treatment for advanced thymic carcinoma patients. Studies have shown that the vascular endothelial growth factor receptor 2(VEGFR-2) is overexpressed in patients with thymic carcinoma. Apatinib, a small molecule tyrosine kinase inhibitor of VEGFR-2, inhibits tumor angiogenesis. In this case, apatinib was selected in the treatment of thymic carcinoma. After 3 months of oral medication of apatinib, the lesions were shrunk, and symptoms of chest pain, chest tightness, palpitation and shortness of breath were significantly relieved. The hydrothorax was reduced, and the disease was effectively controlled. The efficacy was evaluated as partial remission(PR). The disease progression-free survival(PFS) was 11.93 months, and the total survival(OS) was 47.47 months. The quality of life of the patients was improved and the survival time was prolonged.
作者
刘建丽
李艺
冯妮
石颖
郭利华
LIU Jianli;LI Yi;FENG Ni;SHI Ying;GOU Lihua(Department of Oncology,Yunnan Hospital of Traditional Chinese Medicine,Kunming,Yunnan 650100,China)
出处
《肿瘤药学》
CAS
2021年第2期252-256,共5页
Anti-Tumor Pharmacy
